CN101057906B - Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application - Google Patents
Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application Download PDFInfo
- Publication number
- CN101057906B CN101057906B CN200610076303A CN200610076303A CN101057906B CN 101057906 B CN101057906 B CN 101057906B CN 200610076303 A CN200610076303 A CN 200610076303A CN 200610076303 A CN200610076303 A CN 200610076303A CN 101057906 B CN101057906 B CN 101057906B
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- chinese medicine
- concentrated solution
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a Chinese medicinal composition and pharmaceutical preparation for treating hepatitis, which is prepared from picrorhiza rhizome, giant knotweed rhizome, honeysuckle flower and Chinese aspidium, and can be prepared into dosage forms of capsules, tablets, granules, oral liquids and other pharmaceutically acceptable dosage forms.
Description
Technical field
The invention belongs to the development of Chinese herb products technical field.Be specifically related to a kind of Chinese medicine composition and preparation thereof for the treatment of hepatitis, the present invention also provides the preparation method of this Chinese medicine composition.
Background technology
Hepatitis is crowd's frequently-occurring disease, commonly encountered diseases, is one of disease of harm humans health.Especially hepatitis B, route of infection complexity, the sickness rate height, the course of disease is long, easily repeatedly, easy chronicity, part patient can develop into liver cirrhosis and hepatocarcinoma.
Hepatitis B is the infectious disease that is caused by hepatitis B virus, and the whole world has 200,000,000 7 thousand ten thousand people approximately according to the preliminary statistics, Asia and West Pacific region about 1.68 hundred million.China belongs to the hepatitis B district occurred frequently, and hepatitis B virus carriers accounts for 10% of total population, has surpassed 100,000,000 people.Though the reason of known infection is relevant with type, quantity, variation and infected sex, age, immunity, heredity and the liver extent of damage and the treatment present situation of virus, but because the biological behaviour of hepatitis virus molecular biological characteristic, strain and the infected's immunne response mechanism are still lacked enough understanding, hepatitis chronicity mechanism is not understood as yet, treating hepatitis B does not still have effect method so far, will bring adverse consequences as malpractice.
At present the doctor trained in Western medicine multiselect with nucleoside analog (as the lamivudine class etc.) antiviral agents, interferon, anti-inflammatory agent (as the glycyrrhizic acid preparation etc.) though etc. medicine treating hepatitis B is had certain curative effect, but the effect of a lot of medicines awaits further to confirm, and price is expensive mostly, side effect is many, can not be widely used.Therefore, a lot of research worker with target diversion the exploitation of Chinese medicine.Many immunostimulants or antiviral drugs are arranged, if can probably filter out a collection of effective good medicine in the Chinese medicine of China in strict accordance with the operation of new drug development test specification.Over past ten years, a lot of Chinese medicine circle personages do a lot of work on the treatment hepatitis B, and obtain some progress.
Summary of the invention
The object of the present invention is to provide the Chinese medicine composition of a kind of compatibility science, determined curative effect, safe, quality controllable treatment hepatitis.
The realization of the object of the invention is based on understanding and the Therapeutic Principle of motherland's medical science to hepatitis mechanism, select for use Rhizoma Picrorhizae, Rhizoma Polygoni Cuspidati, Flos Lonicerae, Rhizoma Osmundae to combine, can make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat hepatitis.Wherein Rhizoma Picrorhizae has the clearing away damp-heat effect; The effect of Rhizoma Polygoni Cuspidati tool clearing away heat-damp and promoting diuresis, promoting the function of the gallbladder to alleviate jaundice, blood circulation promoting and blood stasis dispelling, Flos Lonicerae, Rhizoma Osmundae have heat-clearing and toxic substances removing, the merit of removing heat from blood, three medicines same usefulness in back helps the Rhizoma Picrorhizae clearing away heat-damp and promoting diuresis eliminating evil.
Above-mentioned Chinese medicine composition mainly is to be made by following bulk drugs: 400～450 parts of Rhizoma Picrorhizae, 50～100 parts of Rhizoma Polygoni Cuspidati, 250～300 parts of Flos Loniceraes, 100～150 parts of Rhizoma Osmundae.Wherein best group becomes 432 parts of Rhizoma Picrorhizae, 86 parts of Rhizoma Polygoni Cuspidati, 133 parts of 266 parts of Flos Loniceraes and Rhizoma Osmundae.The preparation method of said composition is as follows:
A. with the Rhizoma Picrorhizae of described weight proportion with 20%～95% soak with ethanol, percolation extracts, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1;
B. with the Flos Lonicerae of described weight proportion, Rhizoma Polygoni Cuspidati, Rhizoma Osmundae with 20%～95% soak with ethanol, reflux, extract,, extracting solution is at 50 ℃～70 ℃, vacuum is-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating, concentrated solution 2;
C. merge 2,50 ℃～70 ℃ vacuum dryings of concentrated solution 1 and concentrated solution, it is ground into powder, make this Chinese medicine composition.
In order to reach better therapeutic, medicine of the present invention also makes up with the Radix Salviae Miltiorrhizae and the Rhizoma Atractylodis Macrocephalae.The Radix Salviae Miltiorrhizae hardship is slightly cold, and the effect of blood circulation promoting and blood stasis dispelling is arranged, in case coagulation of QI-blood; Rhizoma Atractylodis Macrocephalae spleen invigorating QI invigorating, the dampness diuretic has the power of monarch drug damp eliminating, and prevents all medicine bitter cold impairment of the spleens.All medicines are harmonious, the effect of play heat clearing away, dampness removing altogether, detoxify, invigorating blood circulation.
The consumption of drug component of the present invention can also be: 400～450 parts of Rhizoma Picrorhizae, 50～100 parts of Rhizoma Polygoni Cuspidati, 250～300 parts of Flos Loniceraes, 100～150 parts of Rhizoma Osmundae, 50～100 parts of 100～150 parts of the Radix Salviae Miltiorrhizaes and the Rhizoma Atractylodis Macrocephalaes.Wherein best group becomes 432 parts of Rhizoma Picrorhizae, 86 parts of Rhizoma Polygoni Cuspidati, 266 parts of Flos Loniceraes, 133 parts of Rhizoma Osmundae, 86 parts of 106 parts of the Radix Salviae Miltiorrhizaes and the Rhizoma Atractylodis Macrocephalaes.
The preparation method of above-mentioned medicine may further comprise the steps:
A. with the Rhizoma Picrorhizae of described weight proportion and Radix Salviae Miltiorrhizae with 20%～95% soak with ethanol, percolation extracts, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1;
B. with the Flos Lonicerae of described weight proportion, Rhizoma Polygoni Cuspidati, Rhizoma Osmundae, the Rhizoma Atractylodis Macrocephalae with 20%～95% soak with ethanol, reflux, extract,, extracting solution is at 50 ℃～70 ℃, vacuum is-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating, concentrated solution 2;
C. merge 2,50 ℃～70 ℃ vacuum dryings of concentrated solution 1 and concentrated solution, it is ground into powder, make this Chinese medicine composition.
The preparation method of medicine of the present invention is the physicochemical property according to a few flavor medical materials in the medicament composing prescription, by positive quadraturing design test, is to investigate index finally to determine with the content of effective.
Rhizoma Picrorhizae is monarch drug in the prescription, and pharmacological research shows that the picrorhiza iridoid glycosides compound has the pharmacologically active of hepatic cholagogic preferably, is the main effective ingredient of Rhizoma Picrorhizae treatment hepatitis.Contain polar functional group in the iridoid glycosides molecular structure of compounds, polarity is bigger, is soluble in hydrophilic solvent, the general solvent method that adopts during extraction.Often select for use water, ethanol as extracting solvent, can adopt the method for percolation or backflow to extract.Water and ethanol are cheap and easy to get, and toxicity is little, are accepted by commercial production easily.Effective component in red sage is salvianolic acid and tanshinone compound, symptom, sign, liver function and the hepatic fibrosis serological index that improves chronic active hepatitis B companion early stage liver cirrhosis person, anti peroxidation of lipid liver damage patient had positive effect, and its effective ingredient also useable solvents method extracts; Effective ingredient of honeysuckle is chlorogenic acid and triterpene saponin constituents, the Rhizoma Polygoni Cuspidati active component is diphenylethylene and anthraquinone analog compound, Rhizoma Atractylodis Macrocephalae effective ingredient is to be the liposoluble constituent of representative with the atractylodes lactone, the Rhizoma Osmundae effective ingredient is the Filixic Acids constituents, all available ethanol extraction, for improving extraction efficiency, adopt ethanol refluxing process to extract.
Pharmaceutical composition of the present invention can be made clinical acceptable peroral dosage form by tradition or modern production technology with acceptable auxiliary on the pharmaceutics, as capsule, tablet, granule, oral liquid etc.Used excipient substance can be: starch, sucrose, lactose, stevioside, micropowder silica gel, microcrystalline Cellulose sodium, gelatin, glycerol, Tween 80, Pulvis Talci etc.Owing to need long-term prescription clinically, make solid preparation store convenient, patient's taking convenience, also meeting the market requirement more.Preferred dosage form is a capsule, and mainly consider: 1. the capsule disintegration rate is fast, can reach effective blood drug concentration rapidly, and bioavailability is higher, can bring into play drug effect rapidly; 2. capsule can be covered the bitterness of medicine itself, and have transportation, carry, characteristics such as taking convenience; 3. capsule preparation technology is simple, and cost is low, and quality is easy to control.
Medicine of the present invention has the liver soothing and the spleen invigorating, and the merit that heat-clearing and toxic substances removing, dampness removing are invigorated blood circulation cures mainly hepatitis, comprises acute or chronic hepatitis B, and hepatitis B is also had better therapeutic effect.
In order further to set forth the therapeutic effect of medicine of the present invention, the Chinese medicine composition that adopts the embodiment of the invention 2 to make carries out following pharmacodynamic experiment, and the present invention is further elaborated, but the present invention is not limited to the content that comprises in the following experiment.
Test example 1 Chinese medicine composition is to carbon tetrachloride (CCl
4) cause the prevention protective effect of chmice acute hepatic injury
Compositions little (1.5g crude drug/kg), in (3.0g crude drug/kg) and big (the 6.0g crude drug/kg) three dosage are irritated the stomach Kunming mouse respectively, 1 time/day, continuous 10 days, the 9th day every group of lumbar injection 0.1%CCl of administration
4Peanut oil solution 0.1ml/10g causes the acute liver damage model, detects the content of every animal serum ALT, AST after 16 hours.Result of the test sees Table 1, table 2.
Table 1 compositions is to mice CCl
4The influence of acute liver damage Serum ALT (x ± s)
Annotate: compare ###P＜0.001 with the normal control group; Compare * * P＜0.01, * * * P＜0.001 with model control group
By last table result as seen, compare with normal group, model group ALT value is rising (P＜0.001) obviously; Positive group compares with model group, and the ALT value obviously reduces (P＜0.01).Each dosage group of compositions and model group compare, and the ALT value obviously reduces (P＜0.01).
Table 2 compositions is to mice CCl
4The influence of acute liver damage serum AST (x ± s)
Annotate: compare ###P＜0.001 with the normal control group; Compare * * P＜0.01, * * * P＜0.001 with model control group
By last table result as seen, compare with normal group, model group AST value is rising (P＜0.001) obviously; And positive group compares with model group, though the AST value has reduction, and there was no significant difference (P＞0.05); Each dosage group of compositions and model group compare, and the AST value obviously reduces (P＜0.01 or P＜0.001).
The result shows that the ALT of the large, medium and small dosage group of compositions, AST value relatively have remarkable reduction with model group after modeling.The prompting said composition is to CCl
4The chmice acute hepatic injury of bringing out has certain prevention protective effect.
Test example 2 Chinese medicine compositions are to carbon tetrachloride (CCl
4) cause the therapeutical effect of rat chronic hepatic injury
The Wistar rat, subcutaneous injection 25%CCl
4Peanut oil solution 2ml/kg 2 times weekly, in continuous 8 weeks, causes chronic hepatic injury.Inject CCL in first
4The 2nd day of Oleum Arachidis hypogaeae semen, irritate respectively the capsule for treating gastropathy agent little (1.0g crude drug/kg), in (2.0g crude drug/kg) and big (three dosage of 4.0g crude drug/kg), every day 1 time, continuous 8 weeks, get blood behind administration the 6th, 8 all sockets of the eye, observation group's compound is to the influence of Serum ALT, AST, TP, ALB and liver glycogen and hydroxyproline, and result of the test sees Table 3, table 4, table 5.
Table 3 compositions is to CCl
4Cause the influence (x ± s) of treatment administration 6 all serum AST, the ALT of rat chronic hepatic injury
Annotate: compare ###P＜0.001 with the normal control group; Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with model control group
By last table result as seen, in 6 weeks of administration, model group AST, ALT value obviously raise, and with normal group significant difference (P＜0.001) are arranged relatively; Positive group ALT value obviously reduces, and with model group significant difference (P＜0.001) is arranged relatively, reduces though the AST value has to a certain degree, compares there was no significant difference (P＞0.05) with model group; Each dosage group AST of compositions, ALT value all have to a certain degree reduction, with model group significant difference (P＜0.05, P＜0.01 or P＜0.001) are in various degree arranged relatively.
Table 4 compositions is to CCl
4Cause the influence (x ± s) of treatment administration 8 all serum AST, the ALT of rat chronic hepatic injury
Annotate: compare ###P＜0.001 with the normal control group; Compare * P＜0.05, * P＜0.01, * * * P＜0.001 with model control group
By last table result as seen, in 8 weeks of administration, model group AST, ALT value obviously raise, and with normal group significant difference (P＜0.001) are arranged relatively; Positive group ALT value obviously reduces, and with model group significant difference (P＜0.001) is arranged relatively, reduces though the AST value has to a certain degree, compares there was no significant difference (P＞0.05) with model group; Each dosage group ALT of compositions has to a certain degree reduction, with model group significant difference (P＜0.01 or P＜0.001) is arranged relatively, and AST has to a certain degree reduction, and wherein compositions big or middle dosage group AST and model group relatively have significant difference (P＜0.05).
Table 5 compositions is to CCl
4Cause the influence (x ± s) of treatment administration 6 all serum T P, the ALB of rat chronic hepatic injury
Annotate: compare ##P＜0.01 with the normal control group; Compare * P＜0.05, * * P＜0.01 with model control group
By last table result as seen, in 6 weeks of administration, model group TP, ALB value obviously reduce, and with normal group significant difference (P＜0.01) are arranged relatively; Positive group TP, ALB value have certain rising, but compare there was no significant difference (P＞0.05) with model group; Each dosage group TP of compositions, ALB value all have to a certain degree rising, and wherein big or middle dosage group of compositions and model group relatively have significant difference (P＜0.05 or P＜0.01).
Table 6 compositions is to CCl
4Cause the influence (x ± s) of treatment administration 8 all serum T P, the ALB of rat chronic hepatic injury
Annotate: compare ###P＜0.001 with the normal control group; Compare * P＜0.05, * * * P＜0.001 with model control group
By last table result as seen, in 8 weeks of administration, model group TP, ALB value obviously reduce, and with normal group significant difference (P＜0.001) are arranged relatively; Positive group TP, ALB value have certain rising, with model group significant difference (P＜0.05) are arranged relatively; Each dosage group TP of compositions, ALB value all have to a certain degree rising, and wherein big or middle dosage group and model group relatively have significant difference (P＜0.01).
Table 7 compositions is to CCl
4Cause the influence (x ± s) of rat chronic hepatic injury serum liver glycogen, hydroxyproline
Annotate: compare ###P＜0.001 with the normal control group; Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with model control group
By last table result as seen, the model group hepatic glycogen reduces, and with normal group utmost point significant difference (P＜0.001) is arranged relatively; Though positive group hepatic glycogen has rising, compares there was no significant difference (P＞0.05) with model group; Each dosage group hepatic glycogen of compositions raises, and with model group significant difference (P＜0.05 or P＜0.001) is arranged relatively.
The model group hydroxyproline obviously raises, and with normal group utmost point significant difference (P＜0.001) is arranged relatively; Though positive group hydroxyproline has reduction, compares there was no significant difference (P＞0.05) with model group; Each dosage group hydroxyproline of compositions reduces, and with model group significant difference (P＜0.01 or P＜0.001) is arranged relatively.
Test example 3 Chinese medicine compositions are to the inhibitory action research of DHB
1 age in days Beijing duck, intravenous injection sheldrake DHBV-DNA positive serum, set up the duck hepatitis-B animal model, model group after 7 days (normal saline), positive controls (acyclovir 100mg/kg, be called for short ACV), three dosage of compositions (the continuous oral administration of 10g crude drug/kg, 20g crude drug/kg, 40g crude drug/kg) 10 days, (T before administration
0), the 5th day (T of administration
5), the 10th day (T
10) and drug withdrawal after the 3rd day (P
3) blood sampling, measure the clear middle DHBV-DNA level (0D value) of Sanguis Anas domestica with spot hybridization, and calculate the DHBV-DNA suppression ratio; With S surface antigen (DHBpresAg) level (OD value) before the clear middle DHBV of ELISA method detection Sanguis Anas domestica.This test repeats three batches.Result of the test sees Table 8, table 9, table 10.
The administration of table 8 composition oral is to the influence of the clear DHBV-DNA level of Sanguis Anas domestica
Annotate: the 5th, 10 days (T of administration group administration
5, T
10) and the 3rd day (P of drug withdrawal
3) the clear DHBV-DNA OD of Sanguis Anas domestica value and the preceding (T of infection
0) comparison of OD value, adopt paired t-test; * p＜0.05, * * p＜0.01, * * * P＜0.001;
As seen from the above table, in three batches of experiments, model group oral normal saline the 5th day, 10 days and withdraw back the 3rd day serum DHBV-DNA level and administration before relatively, there is no significant difference, point out in three batches of experimental model groups whole process 13 days serum DHBV-DNA level steady substantially.
Table 9 compositions is to the suppression ratio of the clear DHBV-DNA of Sanguis Anas domestica
By table 9 as seen, each dosage group oral administration of compositions all has in various degree inhibitory action to the clear DHBV-DNA of Sanguis Anas domestica, and certain dose-effect relationship is arranged, heavy dose of group can reach about 70% the suppression ratio of DHBV-DNA, and the clear DHBV-DNA of Sanguis Anas domestica is still had certain inhibitory action in the 3rd day after the drug withdrawal.
The administration of table 10 composition oral is to the influence of the clear DHBpresAg level of Sanguis Anas domestica
Annotate: the 5th, 10 days (T of administration group administration
5, T
10) and the 3rd day (P of drug withdrawal
3) the clear DHBpresAg OD of Sanguis Anas domestica value and the preceding (T of infection
0) comparison of OD value, adopt paired t-test; * p＜0.05, * * p＜0.01, * * * P＜0.001
As seen from the above table, in three batches of experiments, model group oral normal saline the 5th day, 10 days and withdraw the 3rd day serum DHBpresAg level and the T in back
0It relatively there is no significant difference, illustrates that three batches of omnidistance 13 days inner model group serum DHBpresAg levels of experiment are steady substantially.
In three batches of experiments, comparing before the 5th, 10 days serum DHBpresAg level of positive administration group administration and the administration all has remarkable decline (P＜0.001 or P＜0.01 or P＜0.05); In first and second batch experiment, compared obvious decline (P＜0.05) before the 3rd day serum DHBpresAg level and the administration after the drug withdrawal of positive administration group, but in the 3rd batch of experiment, do not had significant difference.Point out this Chinese medicine composition oral administration that dhbv dna is had to a certain degree inhibitory action.
From above experimental study as seen, Drug therapy hepatitis effect of the present invention is obvious, have protect the liver, the effect of transaminase lowering, inhibition hepatitis B virus, do not have bounce-back, safety range is big, toxic and side effects is little.
Specific embodiment
The present invention further elaborates preparation method and its pharmaceutical preparation of this Chinese medicine composition by following examples, but the invention is not restricted to this scope of embodiments.
The preparation method of embodiment 1 Chinese medicine composition of the present invention
400g is ground into coarse granule with Rhizoma Picrorhizae, with 50% soak with ethanol after 15 hours percolation extract, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1; Flos Lonicerae 250g, Rhizoma Polygoni Cuspidati 50g, Rhizoma Osmundae 100g are added 8 times of amount 60% soak with ethanol 1 hour, reflux, extract, 2 times, extracting solution is at 50 ℃～70 ℃, and vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 2; Merge 2,50 ℃～70 ℃ of concentrated solution 1 and concentrated solutions, vacuum is-0.085～-the 0.1MPa condition under vacuum drying 6 hours, be ground into powder, make this Chinese medicine composition.
The preparation method of embodiment 2 Chinese medicine compositions of the present invention
Rhizoma Picrorhizae 432g, Radix Salviae Miltiorrhizae 106g are ground into coarse granule, with 70% soak with ethanol after 12 hours percolation extract, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1; Flos Lonicerae 266g, Rhizoma Polygoni Cuspidati 86g, Rhizoma Atractylodis Macrocephalae 86g, Rhizoma Osmundae 133g are added 8 times of amount 80% soak with ethanol 0.5 hour, reflux, extract, 2 times, extracting solution is at 50 ℃～70 ℃, and vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 2; Merge 2,50 ℃～70 ℃ of concentrated solution 1 and concentrated solutions, vacuum is-0.085～-the 0.1MPa condition under vacuum drying 6 hours, be ground into powder, make this Chinese medicine composition.
The preparation method of embodiment 3 Chinese medicine compositions of the present invention
Rhizoma Picrorhizae 450g, Radix Salviae Miltiorrhizae 150g are ground into coarse granule, with 95% soak with ethanol after 8 hours percolation extract, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1; Flos Lonicerae 300g, Rhizoma Polygoni Cuspidati 100g, Rhizoma Atractylodis Macrocephalae 100g, Rhizoma Osmundae 150g are added 10 times of amount 95% soak with ethanol 0.5 hour, reflux, extract, 2 times, extracting solution is at 50 ℃～70 ℃, vacuum is-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrate, concentrated solution 2 got; Merge 2,50 ℃～70 ℃ of concentrated solution 1 and concentrated solutions, vacuum is-0.085～-the 0.1MPa condition under vacuum drying 6 hours, be ground into powder, make this Chinese medicine composition.
The preparation method of embodiment 4 Chinese medicine compositions of the present invention
432g is ground into coarse granule with Rhizoma Picrorhizae, with 40% soak with ethanol after 8 hours percolation extract, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1; Flos Lonicerae 280g, Rhizoma Polygoni Cuspidati 90g, Rhizoma Osmundae 120g are added 10 times of amount 30% soak with ethanol 1.5 hours, reflux, extract, 2 times, extracting solution is at 50 ℃～70 ℃, and vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 2; Merge 2,50 ℃～70 ℃ of concentrated solution 1 and concentrated solutions, vacuum is-0.085～-the 0.1MPa condition under vacuum drying 6 hours, be ground into powder, make this Chinese medicine composition.
The preparation method of embodiment 5 Chinese medicine composition tablets of the present invention
Get the Chinese medicine composition that embodiment 1 makes and sieve, add pregelatinized Starch, mix homogeneously, tabletting, promptly.
The preparation method of embodiment 6 Chinese medicinal composition capsules agent of the present invention
Get the Chinese medicine composition that embodiment 2 makes and sieve, add starch and micropowder silica gel, mix homogeneously divides the capsule of packing into No. 1, promptly.
The preparation method of embodiment 7 Chinese medicinal composition granules of the present invention
Get the Chinese medicine composition that embodiment 3 makes and sieve, add starch, microcrystalline Cellulose sodium etc., mix homogeneously is granulated, promptly.
The preparation method of embodiment 8 Chinese medicine composition oral liquids of the present invention
Get the Chinese medicine composition that embodiment 4 makes and sieve, mix homogeneously adds lactose and an amount of stevioside's flavoring, promptly.
Claims (11)
1. a Chinese medicine composition for the treatment of hepatitis is characterized in that said composition mainly is to be made by following bulk drugs: 400～450 parts of Rhizoma Picrorhizae, 50～100 parts of Rhizoma Polygoni Cuspidati, 250～300 parts of Flos Loniceraes, 100～150 parts of Rhizoma Osmundae.
2. Chinese medicine composition according to claim 1, wherein the weight portion of each crude drug is: 432 parts of Rhizoma Picrorhizae, 86 parts of Rhizoma Polygoni Cuspidati, 133 parts of 266 parts of Flos Loniceraes and Rhizoma Osmundae.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that the preparation method of said composition is as follows:
A. with the Rhizoma Picrorhizae of described weight proportion with 20%～95% soak with ethanol, percolation extracts, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition under, decompression recycling ethanol, and concentrating must concentrated solution 1;
B. with the Flos Lonicerae of described weight proportion, Rhizoma Polygoni Cuspidati, Rhizoma Osmundae with 20%～95% soak with ethanol, reflux, extract,, extracting solution is at 50 ℃～70 ℃, vacuum is-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating, concentrated solution 2;
C. merge 2,50 ℃～70 ℃ vacuum dryings of concentrated solution 1 and concentrated solution, it is ground into powder, make this Chinese medicine composition.
4. Chinese medicine composition for the treatment of hepatitis is characterized in that said composition made by following bulk drugs: 400～450 parts of Rhizoma Picrorhizae, 50～100 parts of Rhizoma Polygoni Cuspidati, 250～300 parts of Flos Loniceraes, 100～150 parts of Rhizoma Osmundae, 100～150 parts of Radix Salviae Miltiorrhizaes, 50～100 parts of the Rhizoma Atractylodis Macrocephalaes.
5. Chinese medicine composition according to claim 4, wherein the weight portion of each crude drug is: 432 parts of Rhizoma Picrorhizae, 86 parts of Rhizoma Polygoni Cuspidati, 266 parts of Flos Loniceraes, 133 parts of Rhizoma Osmundae, 86 parts of 106 parts of the Radix Salviae Miltiorrhizaes and the Rhizoma Atractylodis Macrocephalaes.
6. according to claim 4 or 5 described Chinese medicine compositions, it is characterized in that the preparation method of said composition is as follows:
A. with the Rhizoma Picrorhizae of described weight proportion and Radix Salviae Miltiorrhizae with 20%～95% soak with ethanol, percolation extracts, extracting solution is at 50 ℃～70 ℃, vacuum be-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating must concentrated solution 1;
B. with the Flos Lonicerae of described weight proportion, Rhizoma Polygoni Cuspidati, Rhizoma Osmundae, the Rhizoma Atractylodis Macrocephalae with 20%～95% soak with ethanol, reflux, extract,, extracting solution is at 50 ℃～70 ℃, vacuum is-0.085～-the 0.1MPa condition, decompression recycling ethanol, and concentrating, concentrated solution 2;
C. merge 2,50 ℃～70 ℃ vacuum dryings of concentrated solution 1 and concentrated solution, it is ground into powder, make this Chinese medicine composition.
7. a Chinese medicine preparation for the treatment of hepatitis is characterized in that making oral formulations by acceptable auxiliary combination on arbitrary described Chinese medicine composition of claim 1～6 and the pharmaceutics.
8. Chinese medicine preparation according to claim 7 is characterized in that oral formulations is capsule, tablet, granule or oral liquid.
9. Chinese medicine preparation according to claim 8 is characterized in that dosage form is a capsule.
10. the application of the described Chinese medicine composition of the arbitrary claim of claim 1～6 in preparation treatment hepatitis medicament.
11. application according to claim 10 is characterized in that the application in preparation treatment hepatitis B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610076303A CN101057906B (en) | 2006-04-20 | 2006-04-20 | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610076303A CN101057906B (en) | 2006-04-20 | 2006-04-20 | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101057906A CN101057906A (en) | 2007-10-24 |
| CN101057906B true CN101057906B (en) | 2010-05-12 |
Family
ID=38864309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610076303A Active CN101057906B (en) | 2006-04-20 | 2006-04-20 | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101057906B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612363B (en) * | 2009-08-07 | 2014-08-06 | 张喜田 | Natural medicinal preparation for raising albumin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298705A (en) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | Chinese medicine for treating hepatitis B and its preparing process |
-
2006
- 2006-04-20 CN CN200610076303A patent/CN101057906B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298705A (en) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | Chinese medicine for treating hepatitis B and its preparing process |
Non-Patent Citations (4)
| Title |
|---|
| 王永兵，毛福林，王强，朱荃.中草药治疗乙型肝炎的研究进展.中国野生植物资源19 5.2000,19(5),5-8. |
| 王永兵,毛福林,王强,朱荃.中草药治疗乙型肝炎的研究进展.中国野生植物资源19 5.2000,19(5),5-8. * |
| 钟有添，王小丽，辜宝祥.中医药治疗病毒性乙型肝炎研究进展.赣南医学院学报24 2.2004,24(2),224-227. |
| 钟有添,王小丽,辜宝祥.中医药治疗病毒性乙型肝炎研究进展.赣南医学院学报24 2.2004,24(2),224-227. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101057906A (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100384467C (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN101112541A (en) | Entecavir medicinal composition and uses thereof | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN1593472A (en) | Pharmaceutical composition for treating liver diseases and its application | |
| CN1977852B (en) | Medicinal composition containing stilbene total glycoside and its use for pharmaceutical treating hepatitis B | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN104435977A (en) | Medicine for treating liver injuries and preparation method of medicine | |
| CN100457140C (en) | Pharmaceutical composition containing lamivudine | |
| CN1795901B (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN103006781A (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN1087617C (en) | Hepatitis curing capsule | |
| CN1312169C (en) | Preparation of gentian effective part and its application | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN1814250B (en) | Chinese medicine composition for treating liver cirrhosis ascites and preparation method thereof | |
| CN101491574A (en) | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof | |
| CN102068658B (en) | Chinese medicine composite for clearing heat, detoxicating, dispelling dampness and eliminating stagnation and preparation method thereof | |
| CN101147757A (en) | Traditional Chinese medicine for treating chronic hepatitis B and its preparation process | |
| CN102008588B (en) | Medicine composition for curing hepatic encephalopathy and hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU LVKAI GROWTH INVESTMENT CENTER (LIMITED PAR Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150113 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 215125 SUZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150113 Address after: 215125, 456, Pratt & Whitney Road, Suzhou Industrial Park, Jiangsu Patentee after: Suzhou green growth investment center (limited partnership) Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |